Regado Biosciences, Inc. is a biopharmaceutical company discovering and developing antithrombotic drug systems for acute and sub-acute cardiovascular and other indications. The company’s lead product includes REG1, an anticoagulant in clinical trials for use in patients with cardiovascular conditions who are undergoing coronary intervention. The company’s products under development also include REG2 for venous thrombosis indications treatment; and REG3, an antiplatelet therapy for diabetic vasculopathy and other inflammatory diseases. For more information, visit the company’s website at www.regadobio.com.